From a Nation of Comrades to VIP Individuals: The Paradigm Shift Called Precision Medicine
Dr. Emad Hassan, CDMO Pharmaceutical Executive, Hope Life Sciences LLC
For more than a century, medicine has advanced by identifying similarities among patients and developing standardised therapies for large populations. Precision medicine represents a fundamental philosophical shift toward understanding biological individuality. This article explores how healthcare is evolving from population-based treatment toward patient-centred optimisation, redefining disease, therapy, pharmaceutical development, and the future mission of healthcare professionals.
Introduction
Every scientific era is defined by a central question. For much of the twentieth century, a simple but extraordinarily successful one guided medicine: What do patients have in common? That question shaped the entire healthcare ecosystem. It influenced how diseases were defined, how clinical trials were designed, how medicines were manufactured, and how regulators evaluated therapeutic success. Most importantly, it shaped how pharmaceutical scientists thought about their mission.
I entered pharmaceutical sciences during an era when the profession's greatest achievements were measured by our ability to create consistency. Better manufacturing processes, more reproducible dosage forms, greater uniformity, and larger production scales represented the highest standards of excellence. The philosophy was straightforward: if a medicine was proven safe and effective, the challenge was to deliver that medicine reliably to as many patients as possible. The tablet became the symbol of that era a small, elegant object manufactured by the billions, identical in appearance, composition, and performance. It represented one of humanity's greatest achievements: the ability to transform scientific discovery into therapeutic benefit on a massive scale.
The success of this model is undeniable. Modern pharmacotherapy has dramatically improved the management of infectious diseases, cardiovascular disorders, endocrine conditions, and countless other illnesses. Yet beneath this success lay a question that never completely disappeared. Why did patients receiving the same medicine sometimes experience different outcomes? Physicians observed it routinely. Some patients responded rapidly, others more slowly. Some required dose adjustments, while others experienced adverse effects at standard doses. For many years, these differences were regarded as unavoidable biological noise within an otherwise effective system.
As scientific tools improved, however, variability became increasingly difficult to dismiss. The deeper researchers looked into human biology, the more individuality they discovered. Differences in genetics, metabolism, immune function, microbiome composition, and disease mechanisms revealed that patients sharing the same diagnosis were often biologically distinct. What appeared to be a single disease frequently concealed multiple biological realities. What appeared to be a homogeneous patient population often represented countless individual variations.
Gradually, medicine arrived at a profound realisation: patients sharing the same diagnosis are not necessarily sharing the same disease. The clinical label may be identical, but the underlying biology may differ significantly. This realisation may ultimately be remembered as one of the most important turning points in modern healthcare, not because it introduced a new technology or a new regulatory pathway, but because it changed the question that medicine was asking.
For much of the last century, medicine searched for similarity. Increasingly, this century is searching for individuality. That transition is what we call precision medicine. While precision medicine is often described through the lens of genomics, biomarkers, artificial intelligence, advanced diagnostics, and targeted therapies, these technologies are best viewed as consequences rather than causes. The true revolution is philosophical. Healthcare is gradually moving from a system organised around groups toward a system organised around individuals.
I sometimes describe this transformation as a movement from a nation of comrades to a society of VIP individuals. The comparison is not political; it is scientific. The comrade model assumes that members of a group are sufficiently alike to benefit from similar interventions. The VIP model assumes that each individual deserves a deeper biological understanding before therapeutic decisions are made. One seeks commonality; the other seeks individuality. One asks, "What works for most patients?" The other asks, "What works for this patient?"
This distinction may appear subtle, but it changes everything. It influences how diseases are classified, how therapies are developed, how clinical evidence is interpreted, and how future healthcare systems may operate. It may ultimately change how pharmaceutical scientists define their profession. For most of my career, pharmaceutical sciences have focused on reducing variability in products. The emerging challenge is different: understanding variability in patients. That represents a remarkable reversal. For decades, we worked to make products more alike; now we are working to understand why people are different.
The twentieth century was the age of standardisation. The twenty-first century may become the age of personalisation. Neither era diminishes the achievements of the other. The first made modern medicine possible. The second may make modern medicine smarter. The first taught us how to manufacture therapeutic similarity on an unprecedented scale. The second is teaching us how to respect biological individuality on an unprecedented scale.
Perhaps that is the deepest meaning of precision medicine. It is not ultimately the triumph of genetics, artificial intelligence, or any particular technology. It is the recognition that behind every diagnosis stands an individual human being whose biology may be more unique than medicine once imagined. The twentieth century taught us how to treat diseases. The twenty-first century is teaching us how to understand patients. That may prove to be the most important therapeutic advance of all.
Emad Hassan, PhD, is a pharmaceutical scientist with academic training from the University of Georgia College of Pharmacy and the Faculty of Pharmacy, Alexandria University. His career has spanned academia, therapeutic drug monitoring, pharmaceutical tech
